Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 12.33% is 146% above its 5-year average of 5.01%, around the middle of its 5-year range (-85.35%–56.18%).
As of the fiscal period ended Tuesday, June 30, 2026. 45.18% above its 12-month average of 8.49%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 12.33%.
RETURN ON EQUITY (ROE)
12.33%
RETURN ON EQUITY (ROE) AVG TTM
8.49%
RETURN ON EQUITY (ROE) AVG 3Y
2.34%
RETURN ON EQUITY (ROE) AVG 5Y
5.01%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+45.18%
CURRENT VS 3Y AVG
+427.65%
CURRENT VS 5Y AVG
+145.97%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-40.30%
median of 668 covered companies
CURRENT VS SECTOR MEDIAN
+130.59%
vs the sector median at left
Kiniksa Pharmaceuticals International, plc
Market Cap
$5.73B
Return on Equity (ROE)
12.33%
TTM Avg
8.49%
3Y Avg
2.34%
5Y Avg
5.01%
Market Cap
$5.68B
Return on Equity (ROE)
-21.80%
TTM Avg
-16.70%
3Y Avg
-22.00%
5Y Avg
-23.98%
Market Cap
$5.91B
Return on Equity (ROE)
20.38%
TTM Avg
5.87%
3Y Avg
3.40%
5Y Avg
3.36%
Market Cap
$5.88B
Return on Equity (ROE)
-39.33%
TTM Avg
-54.18%
3Y Avg
-65.89%
5Y Avg
-59.69%
Market Cap
$5.54B
Return on Equity (ROE)
-1.93%
TTM Avg
-0.70%
3Y Avg
0.57%
5Y Avg
0.69%
Market Cap
$5.51B
Return on Equity (ROE)
-9.09%
TTM Avg
-8.34%
3Y Avg
-4.98%
5Y Avg
-4.98%
Market Cap
$6.02B
Return on Equity (ROE)
-15.40%
TTM Avg
-48.41%
3Y Avg
-63.30%
5Y Avg
-53.67%
Market Cap
$5.33B
Return on Equity (ROE)
18.24%
TTM Avg
20.62%
3Y Avg
17.32%
5Y Avg
27.02%
Market Cap
$5.32B
Return on Equity (ROE)
N/A
TTM Avg
-149.71%
3Y Avg
-15.45%
5Y Avg
-6097.55%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | $5.73B | 12.33% | 8.49% | 2.34% | 5.01% |
| CG Oncology Inc. (CGON)vs › | $5.68B | -21.80% | -16.70% | -22.00% | -23.98% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.91B | 20.38% | 5.87% | 3.40% | 3.36% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.88B | -39.33% | -54.18% | -65.89% | -59.69% |
| RadNet, Inc. (RDNT)vs › | $5.54B | -1.93% | -0.70% | 0.57% | 0.69% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.51B | -9.09% | -8.34% | -4.98% | -4.98% |
| GRAIL Inc. (GRAL)vs › | $6.02B | -15.40% | -48.41% | -63.30% | -53.67% |
| Doximity, Inc. (DOCS)vs › | $5.33B | 18.24% | 20.62% | 17.32% | 27.02% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | N/A | -149.71% | -15.45% | -6097.55% |
| Sotera Health Company (SHC)vs › | $5.28B | 24.56% | 11.91% | -7.82% | -3.31% |
ROE
12.3%
ROA
9.0%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 12.33% |
| 2026-03-31 | 12.06% |
| 2025-12-31 | 10.40% |
| 2025-09-30 | 6.71% |
| 2025-06-30 | 0.97% |
| 2025-03-31 | -3.71% |
| 2024-12-31 | -9.85% |
| 2024-09-30 | -2.08% |
| 2024-06-30 | -2.35% |
| 2024-03-31 | 2.00% |
| 2023-12-31 | 3.21% |
| 2023-09-30 | -1.65% |
| 2023-06-30 | 56.18% |
| 2023-03-31 | 50.32% |
| 2022-12-31 | 46.29% |
| 2022-09-30 | 37.13% |
| 2022-06-30 | -73.01% |
| 2022-03-31 | -80.39% |
| 2021-12-31 | -85.35% |
| 2021-09-30 | -81.87% |
| 2021-06-30 | -79.96% |
| 2021-03-31 | -68.14% |
| 2020-12-31 | -51.74% |
| 2020-09-30 | -38.92% |
| 2020-06-30 | -49.02% |
| 2020-03-31 | -59.50% |
| 2019-12-31 | -71.81% |
| 2019-09-30 | -68.54% |
| 2019-06-30 | -61.77% |
| 2019-03-31 | -49.94% |
| 2018-12-31 | -36.96% |
| 2018-09-30 | -29.27% |
| 2018-06-30 | -24.86% |
| 2018-03-31 | -36.95% |
